ARTICLE IN PRESS

YTAAP-12896; No. of pages: 8; 4C:

Toxicology and Applied Pharmacology xxx (2013) xxx-xxx



Contents lists available at ScienceDirect

Toxicology and Applied Pharmacology

journal homepage: www.elsevier.com/locate/ytaap



- The gap junction inhibitor 2-aminoethoxy-diphenyl-borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450
- enzymes and c-jun N-terminal kinase activation
- Kuo Du ^a, C. David Williams ^a, Mitchell R. McGill ^a, Yuchao Xie ^a, Anwar Farhood ^b, Mathieu Vinken ^c, Hartmut Jaeschke ^{a,*}
 - a Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA
 - ^b Department of Pathology, St. David's North Austin Medical Center, Austin, TX 78756, USA
 - ^c Department of Toxicology, Center for Pharmaceutical Sciences, Vrije Universiteit Brussels, 1090 Brussels, Belgium

ARTICLE INFO

11 Article history:

- 12 Received 24 July 2013
- Revised 12 September 2013
- 14 Accepted 13 September 2013
- 15 Available online xxxx

15

47

49

50 51

52

10

19 Keywords:

- Q3 20 Acetaminophen hepatotoxicity
 - 21 Gap junctions22 Connexin32
 - 23 c-jun-N-terminal kinase
 - 24 Protein adducts
 - 25 2-Aminoethoxy-diphenyl-borate
 - 26 Oxidative stress

ABSTRACT

Acetaminophen (APAP) hepatotoxicity is the leading cause of acute liver failure in the US. Although many aspects 27 of the mechanism are known, recent publications suggest that gap junctions composed of connexin32 function as 28 critical intercellular communication channels which transfer cytotoxic mediators into neighboring hepatocytes 29 and aggravate liver injury. However, these studies did not consider off-target effects of reagents used in these ex- 30periments, especially the gap junction inhibitor 2-aminoethoxy-diphenyl-borate (2-APB). In order to assess the 31 mechanisms of protection of 2-APB in vivo, male C56BI/6 mice were treated with 400 mg/kg APAP to cause 32 extensive liver injury. This injury was prevented when animals were co-treated with 20 mg/kg 2-APB and was 33 attenuated when 2-APB was administered 1.5 h after APAP. However, the protection was completely lost 34 when 2-APB was given 4-6 h after APAP. Measurement of protein adducts and c-jun-N-terminal kinase (JNK) 35 activation indicated that 2-APB reduced both protein binding and JNK activation, which correlated with 36 hepatoprotection. Although some of the protection was due to the solvent dimethyl sulfoxide (DMSO), in vitro 37 experiments clearly demonstrated that 2-APB directly inhibits cytochrome P450 activities. In addition, JNK activation induced by phorone and tert-butylhydroperoxide in vivo was inhibited by 2-APB. The effects against APAP 39 toxicity in vivo were reproduced in primary cultured hepatocytes without use of DMSO and in the absence of 40 functional gap junctions. We conclude that the protective effect of 2-APB was caused by inhibition of metabolic 41 activation of APAP and inhibition of the JNK signaling pathway and not by blocking connexin32-based gap 42 junctions.

 $\hbox{@ 2013}$ Published by Elsevier Inc. $\,44$

Introduction

Acetaminophen (APAP) is a widely used analgesic and antipyretic drug, which is safe at therapeutic doses. However, intentional or accidental overdosing can induce severe liver injury and in some patients even acute liver failure (Larson, 2007; McGill et al., 2012). Early animal

Abbreviations: ALT, alanine aminotransferase; APAP, acetaminophen; 2-APB, 2-aminoethoxy-diphenyl-borate; t-BHP, tert-butylhydroperoxide; Cx32, connexin32; DMSO, dimethyl sulfoxide; 7-EFC, 7-ethoxy-4-trifluoromethylcoumarin; GSH, glutathione; HPLC-ECD, high-pressure liquid chromatography with electrochemical detection; JNK, c-jun-N-terminal kinase; p-JNK, phospho-JNK; LDH, lactate dehydrogenase; NAC, N-acetylcysteine; NAPQI, N-acetyl-p-benzoquinone imine; PH, phorone; ROS, reactive oxygen species; TAA, thioacetamide.

E-mail address: hjaeschke@kumc.edu (H. Jaeschke).

0041-008X/\$ – see front matter © 2013 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.taap.2013.09.010 studies identified reactive metabolite formation, glutathione (GSH) de- 54 pletion and protein adduct formation as critical events in the toxicity 55 (McGill and Jaeschke, 2013; Mitchell et al., 1973; Nelson, 1990). This 56 mechanistic insight led to the introduction of N-acetylcysteine (NAC) 57 as a clinical antidote against APAP poisoning (Prescott et al., 1977). 58 NAC promotes GSH synthesis and thus protects by enhancing the detox- 59 ification capacity for the reactive metabolite N-acetyl-p-benzoquinone 60 imine (NAPQI) (Corcoran and Wong, 1986; Corcoran et al, 1985). 61 NAC-supported GSH synthesis also replenishes the mitochondrial GSH 62 content, which allows detoxification of reactive oxygen species and 63 peroxynitrite in the mitochondria (Cover et al., 2005; Knight et al., 64 2002). In addition, surplus NAC not needed to synthesize GSH will be 65 degraded, and the resulting Krebs cycle intermediates support mito- 66 chondrial energy metabolism (Saito et al., 2010b). Despite these multi- 67 ple protective mechanisms of NAC, it is very obvious that NAC is most 68 effective when given as early as possible after the APAP overdose. How- 69 ever, the clinical reality is that many patients only seek medical atten-70 tion when liver injury is already present (Larson, 2007). Therefore, 71

Please cite this article as: Du, K., et al., The gap junction inhibitor 2-aminoethoxy-diphenyl-borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450..., Toxicol. Appl. Pharmacol. (2013), http://dx.doi.org/10.1016/j.taap.2013.09.010

^{*} Corresponding author at: University of Kansas Medical Center, Department of Pharmacology, Toxicology & Therapeutics, 3901 Rainbow Blvd, MS 1018, Kansas City, Kansas 66160, USA. Fax: $+\,1\,913\,588\,7501$.

2

72

73

74 75

76

77 78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

100 101

102

103

104

105

106

107

108

109

110

111

112

113

119

120

121

122

123

124

125

126

127

128

129

130

131

132

there is clearly a need to develop drugs that are effective after the metabolism phase.

A recent paper by Patel et al. (2012) identified gap junctions containing connexin32 (Cx32) as critical intercellular communication channels responsible for the progression of liver injury after thioacetamide (TAA) and APAP overdose. The authors suggested that gap junctions allow the transfer of a lethal dose of reactive oxygen species (ROS) into neighboring hepatocytes. The most remarkable feature of this study was the identification of a small molecule Cx32-gap junction inhibitor, 2-aminoethoxy-diphenyl-borate (2-APB) (Tao and Harris, 2007), which was not only >99% effective in preventing APAP- or TAA-induced liver injury when given 1 h before drug overdose, but also reduced liver injury by 60% when administered as late as 6 h after the toxicants (Patel et al., 2012). This remarkable protection of 2-APB, especially with delayed administration, garnered significant attention (Fromenty, 2013; Maurel and Rosenbaum, 2012). The editorial commentaries expressed the hope that this might be a novel and promising treatment option for drug-induced liver injury. However, the virtually perfect protection with 2-APB raises some concerns regarding the mechanisms involved. Although Patel et al. (2012) evaluated the formation of TAA metabolites, this was not done with APAP. In addition, 2-APB is only soluble in diluted dimethyl sulfoxide (DMSO), which is known to effectively block APAP toxicity through inhibition of drug metabolism even at very low doses (Jaeschke et al., 2006). Given these serious concerns and the potential benefits of 2-APB treatment, we evaluated the mechanism of protection of 2-APB in a murine model of acetaminophen hepatotoxicity in vivo and in cultured mouse hepatocytes.

Materials and methods

Animals. Male C57Bl/6 mice (8–12 weeks old) purchased from Jackson Laboratories (Bar Harbor, ME) were used in our experiments. The mice were kept in an environmentally controlled room with a 12 h light/dark cycle and free access to food and water. All experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Kansas Medical Center and followed the criteria of the National Research Council for the care and use of laboratory animals.

Experiment design. After overnight fasting, mice were treated with 400 mg/kg APAP (Sigma-Aldrich, St. Louis, MO) (i.p.) dissolved in warm saline. A dose of 20 mg/kg of the Cx32 gap junction inhibitor 2-aminoethoxy-diphenyl-borate (2-APB) (Sigma-Aldrich) dissolved in DMSO was administered with APAP, or at 1.5 h, 4.5 h and 6 h after APAP treatment, All vehicle control mice received the same volume of DMSO (0.2 ml/kg) and saline (20 ml/kg). Mice were euthanized at 2 h, 6 h or 24 h after APAP injection and blood and livers were harvested. In addition, some animals were treated with 20 mg/kg 2-APB followed 1 h later by 100 mg/kg phorone (Sigma-Aldrich) dissolved in corn oil and then 1 h later with 1 mmol/kg tert-butylhydroperoxide (tBHP) (Sigma-Aldrich) and euthanized 1 h after tBHP (Xie et al., 2013). Blood was drawn into a heparinized syringe to determine alanine aminotransferase (ALT) activity with a kit from Pointe Scientific (Canton, MI). The liver was removed and pieces were fixed in phosphate-buffered formalin or used for mitochondrial isolation. The rest of the liver was snap-frozen in liquid nitrogen and subsequently stored at -80 °C.

Mouse hepatocyte isolation and cell viability assessment. Primary hepatocytes were isolated from mice by means of a 2-step collagenase perfusion technique as described previously (Bajt et al., 2004). Cell viability was generally more than 90% based on trypan blue exclusion, and cell purity of hepatocytes was more than 95%. The cells were plated in a density of 6×10^5 cells/well in six-well plates (BioCoat collagen I cellware plates; Becton Dickinson, Franklin Lakes, NJ). Cells were grown in Williams E medium (Life Technologies, Grand Island, NY) containing 100 U/ml penicillin/streptomycin, 1×10^{-7} M insulin, and 10% fetal

bovine serum. After 3.5 h of attachment to the bottom of the plate, cells 134 were treated with 5 mM APAP and 2-APB at the same time or delayed 135 for 1.5 h at a concentration of 1, 5, 10, or 25 μ M. Both APAP and 2-APB 136 were dissolved in 37 °C Williams E medium. Cells were harvested for 137 lactate dehydrogenase (LDH) activity, GSH and APAP-protein adduct 138 determination. 139

Measurement of LDH and GSH. The measurement of LDH activities 140 was performed as described in detail (Bajt et al., 2004). In short, after 141 removing the medium, cells were scraped off and lysed in cell lysis 142 buffer (25 mM HEPES, 5 mM EDTA, 0.1% CHAPS, and 1 mg/ml each of 143 pepstatin, leupeptin, and aprotinin). The lysates were sonicated and 144 centrifuged for 10 min at 20,000 g at 4 °C. Both the resulting supernatant and previous cell medium were incubated with potassium phos- 146 phate buffer containing pyruvate and NADH, and LDH activities were 147 determined by the decline of absorbance at 340 nm. GSH levels in 148 primary mouse hepatocyte were determined using a modified Tietze 149 assay (Yan et al., 2010). In brief, primary cells were lysed and homogenized in 3% sulfosalicylic acid and centrifuged to remove precipitated 151 proteins. The supernatant was further diluted with 0.1 M potassium 152 phosphate buffer, pH 7.4. The samples were then assayed with 153 dithionitrobenzoic acid as described (Jaeschke and Mitchell, 1990). A 154 10% sodium dodecyl sulfate solution was applied to the pellet to solubilize the protein. Protein concentrations were determined using the 156 bicinchoninic acid kit (Pierce, Rockford, IL). The GSH levels were 157 expressed per mg protein.

APAP protein adducts and cytochrome P450 activity. APAP-protein adducts in liver tissues were measured by high-pressure liquid chromatography with electrochemical detection (HPLC-ECD) according to the method of Muldrew et al. (2002) with some modifications (Ni et al., 162 2012). APAP-protein adduct concentration in primary mouse hepatocytes was determined as described (McGill et al., 2011). The cytochrome 164 P450 activity was determined using the 14,000 g supernatant from a 165 total liver homogenate in the 7-ethoxy-4-trifluoromethylcoumarin 166 (7EFC) deethylase assay (Buters et al., 1993), as described in detail 167 (Ramachandran et al., 2011). The substrate 7EFC is known to be metabolized by Cyp1A2 and 2E1 (Buters et al., 1993).

Histology and immunoprobing. Formalin-fixed tissue samples were 170 embedded in paraffin and 5 µm thickness sections were cut and stained 171 with hematoxylin and eosin (H&E) for blinded evaluation of tissue ne- 172 crosis as described (Gujral et al., 2002). Western blotting was performed 173 as described in detail previously (Bajt et al., 2000). Briefly, a 20% liver 174 homogenate was prepared for each liver sample in homogenizing buffer 175 (25 mM HEPES, 5 mM EDTA, 2 mM DTT, 0.1% CHAPS supplemented 176 with 1 µg/ml leupeptin, aprotinin and pepstatin) with 10 stroke of a 177 tight fitting Teflon pestle in a mortar. The homogenate was centrifuged 178 at 14,000 g for 20 min and the supernatant was collected. After deter- 179 mination of protein concentration using the bicinchoninic acid kit 180 (Pierce, Rockford, IL), 30 µg of protein was loaded per lane. Western 181 blotting for JNK was performed using rabbit anti-JNK and anti- 182 phospho-INK antibodies (Cell Signaling Technology, Danvers, MA) 183 with horseradish peroxidase-coupled donkey anti-rabbit IgG (Santa 184 Cruz Biotechnology, Santa Cruz, CA) (Bajt et al., 2000). Proteins were vi- 185 sualized by enhanced chemiluminescence (Amersham Pharmacia Bio-186 tech., Inc., Piscataway, NJ).

Statistics. All data were expressed as mean \pm SEM. For normally distributed data, statistical significance was evaluated by one-way analysis 189 of variance (ANOVA), followed by Student Newman–Keul's test for 190 multiple comparisons. For non-normally distributed data, ANOVA was 191 performed on ranks, followed by Dunn's multiple comparisons. P < 0.05 192 was considered significant.

Download English Version:

https://daneshyari.com/en/article/5846449

Download Persian Version:

https://daneshyari.com/article/5846449

Daneshyari.com